Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Summary

Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.

Timeline

Start

2024-06-01

Primary completion

2026-04-01

Completion

2029-04-01

Drugs

Indications